MedTrace Logo

Efficacy and Safety of Alfuzosin for the Treatment of Voiding Dysfunction in Female

NCT00679315 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 190

Last updated 2013-06-10

No results posted yet for this study

Summary

The purpose of this study is to explore the efficacy of Alfuzosin (10 mg, qd) in reducing the score of International Prostate Symptom Score (IPSS) from baseline to 8 weeks of treatment in female patients with voiding dysfunction.

Conditions

  • Voiding Dysfunction

Interventions

DRUG

alfuzosin hydrochloride XL 10mg

One tablet to be taken daily after a meal before bedtime for 8 weeks.

DRUG

Placebo

One tablet to be taken daily after a meal before bedtime for 8 weeks.

Sponsors & Collaborators

  • Handok Inc.

    collaborator INDUSTRY

  • The Korean Urological Association

    collaborator OTHER

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Kyu-Sung Lee, Ph.D · Samsung Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2009-03-31
Completion
2009-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00679315 on ClinicalTrials.gov